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Anti-Human CD73 Monoclonal Antibody Inhibits Metastasis
Formation in Human Breast Cancer by Inducing Clustering
and Internalization of CD73 Expressed on the Surface of
Cancer Cells
Mikkel G. Terp,*,† Kristina A. Olesen,* Eva C. Arnspang,†,‡ Rikke R. Lund,*
B. Christoffer Lagerholm,†,‡ Henrik J. Ditzel,*,†,x and Rikke Leth-Larsen*
Recent studies have shown that Abs that target the cell-surface enzyme CD73 (ecto-59-nucleotidase) reduce growth of primary
tumors and metastasis in syngenic mice by inhibiting the catalytic activity of CD73, and thus increasing the activity of cytotoxic
T lymphocytes. In this article, we report another anticancer mechanism of anti-CD73 Abs and show that an anti-CD73 mAb (AD2)
inhibits metastasis formation by a mechanism independent of CD73 catalytic activity and inhibition of primary tumor growth.
This mechanism involves clustering and internalization of CD73, but does not require cross-linking of CD73, because both whole
IgG anti-CD73 AD2 mAb and Fab9 fragments thereof exhibited this effect. Ex vivo treatment of different breast cancer cell lines
with anti-CD73 AD2 mAb before i.v. injection into mice inhibited extravasation/colonization of circulating tumor cells and
significantly reduced metastasis development. This effect was also observed when the cancer cell-surface expression of CD73
was significantly reduced by small interfering RNA knockdown. The antimetastatic activity is epitope specific, as another Ab that
efficiently binds CD73-expressing live cancer cells did not lead to CD73 internalization and metastasis inhibition. Furthermore,
anti-CD73 AD2 mAb inhibited development of metastasis in a spontaneous animal model of human metastatic breast cancer. Our
study shows that some anti-CD73 mAbs cause cell-surface clustering of CD73 followed by internalization, thus inhibiting the
ability of circulating tumor cells to extravasate and colonize, leading to inhibition of metastasis. Ab-based CD73 cancer therapy
should include a combination of Abs that target the catalytic activity of CD73, as well as those with the characteristics described in
this article. The Journal of Immunology, 2013, 191: 4165–4173.
M
etastasis is a complex process that involves a series of
events, including local invasion, intravasation, survival
in the circulation, extravasation, and ultimately colo-
nization of cancer cells in a distant organ. Many proteins have
been shown to be involved in the metastatic process, including
tumor cell plasma membrane proteins that may cross talk with the
surrounding environment, such as the extracellular matrix and ad-
jacent cells (reviewed in Ref. 1). One of these metastasis-associated
membrane proteins is CD73 (ecto-59-nucleotidase), a 70-kDa GPI-
anchored protein. In a global proteomic analysis of isogenic meta-
static and nonmetastatic breast cancer cell lines, we showed that
CD73 was more highly expressed in metastasizing versus non-
metastasizing cancer cells, and analysis of clinical breast cancer
biopsies demonstrated a correlation between CD73 expression in
primary tumors and risk for distant metastasis (2, 3).
CD73 is ubiquitously expressed in most normal tissues, in-
cluding endothelial and subsets of hematopoietic cells (4); how-
ever, increased levels are present in a number of cancers (5). CD73
has been proposed to have several functions, including cell adhesion
and enzymatic conversion of AMP to adenosine and inorganic
phosphate (6–10). It was recently shown in a murine syngenic breast
cancer model that inhibition of adenosine production using anti-
murine CD73 mAb or a, b-methylene adenosine-59-diphosphate
(APCP) decreased tumor growth. Adenosine is known to inhibit the
effect of CD8+ T cell–mediated response; thus, the mechanism be-
hind the tumor growth inhibition was induction of such CD8+ T cell–
mediated antitumor responses in the absence of adenosine (5, 8).
Inhibiting adenosine production also inhibited metastasis devel-
opment by decreasing migration of cancer cells (8). In addition,
studies in CD73 knockout mice showed that lack of host-derived
CD73 significantly inhibited both tumor growth and metastasis for-
mation, indicating that not only CD73 expressed on cancer cells, but
also CD73 expressed by adjacent normal tissues plays a critical role
in the cancer process (7, 11). Treatment of cancer cells with APCP
or RNA interference silencing of CD73 decreased adhesion to ex-
tracellular matrix proteins, laminin and fibronectin (12). Interestingly,
CD73 RNA interference was shown to inhibit adhesion and invasion
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of cancer cells more potently than APCP, suggesting that the ca-
pacity of CD73 to promote adhesion and invasion may relate to
other mechanisms in addition to its catalytic activity (12).
Although most studies have analyzed murine CD73 in syngenic
mouse models, in this study, we examined the effect of anti-human
CD73 Abs in a human breast cancer xenograft model. Using ad-
vanced live animal bioimaging, we identified an anti-human CD73
Ab that significantly decreased spontaneous metastasis formation
independent of CD73 catalytic activity. The anti-CD73mAb (AD2)
that exhibits this novel mechanism of action alters the normal
distribution of CD73 from being evenly expressed in the membrane
to forming clusters followed by internalization. Blocking cell-
surface–expressed CD73 reduced the ability of cancer cells to ex-
travasate from the circulation and colonize at distant sites.
Materials and Methods
Cell lines, culture, and transfection
The MDA-MB-231 and M4A4 LM3-2 cell lines (American Type Culture
Collection) were transfected with luciferase 2 (LUC2)–expressing lenti-
viral particles (In Vivo Imaging Solutions) using a multiplicity of infection
virus particle concentration of 15 according to the manufacturer’s guide-
lines, generating stably luciferase-expressing MDA-MB-231 LUC2 (MDA-
MB-231) and M4A4 LM3-2 LUC2 (LM3) cell lines. The two cell lines were
maintained in DMEM (Life Technologies, Invitrogen) supplemented with
10% FBS (Life Technologies), 5% penicillin/streptomycin (Life Tech-
nologies). Cultures were grown in humidified atmosphere of 5% CO2 at
37˚C. All cell lines were routinely checked for Mycoplasma infection and
morphology changes, and propagated no longer than 3 mo after resuscitation.
Abs
The mouse anti-human CD73 AD2 mAb (a gift from Prof. L. Thompson,
Oklahoma Medical Research Foundation, Oklahoma City, OK) was pro-
duced at the Immunology Core Facility at the University of North Carolina,
Chapel Hill. The mouse anti-human CD73 IE9 mAb was purchased from
Santa Cruz Biotechnologies. Both mAbs were generated by immunization
with full-length CD73 purified from human placenta (4). The isotype-
matched control mAb was an IgG1k a-Diphtheria toxoid mAb (HYP
123-05; Bioporto). Alexa Flour 555 labeling was performed using Alexa
Fluor 555 mAb Labeling Kit according to the manufacturer’s guidelines
(Invitrogen). The anti-C3d Ab (AF2655) used for immunohistochemical
analysis was purchased from R&D Systems.
Generation of Fab9 fragments of anti-CD73 AD2 mAbs
To generate Fab9 fragments, we initially dialyzed anti-CD73 AD2 mAb
against 100 mM acetate buffer, 1 mM EDTA, pH 4.5, and incubated them
for 72 h with pepsin (5 mg/mg Ab; Sigma-Aldrich). The generated F(ab9)2
fragments were separated by size exclusion chromatography using 100 mM
acetate buffer, 1 mM EDTA, and 50 mM cysteine pH 5.5 on a Superdex 200
HiLoad 16/60 column (GE Healthcare) and incubated for 24 h with papain
(10 mg/mg Ab; Sigma-Aldrich). The generated Fab9 fragments were sep-
arated by size exclusion chromatography using PBS, pH 7.4 on a Superdex
200 HiLoad 16/60 column (GE Healthcare).
CD73 knockdown
Human CD73 small interfering RNA (siRNA; #S9735 and #S9436; Life
Technologies) and scrambled control siRNA (Qiagen, Denmark) was trans-
fected into MDA-MB-231 LUC2 cells either in combination or as single
siRNAs (300 nM) in 100 ml nucleofector solution V (Cell Line Nucle-
ofector Kit V; Amaxa) using an Amaxa Nucleofector II according to the
manufacturer’s guidelines (Lonza Europe). Knockdown was evaluated using
flow cytometry as described later. Injection of the cancer cells in the tail vein
was performed 96 h after transfection.
In vivo studies of anti-CD73 AD2 mAb treatment in
a spontaneous metastasis xenograft model
Subconfluent cells in culture were washed in PBS and harvested by a cell
scraper (Almeco). Cells (1 3 106) were resuspended in a 1:1 mixture of
extracellular matrix from the Engelbreth-Holm-Swarm sarcoma (Sigma-
Aldrich) and DMEM before inoculation. Orthotopic transplantation of can-
cer cells was performed by injection into a surgically exposed mammary gland
of anesthetized 8-wk-old female CB-17 SCID mice (Taconic). Anti-CD73
AD2 mAb (5 mg/kg) and control mAb (5 mg/kg) were injected i.p. 4 d
after cancer cell transplantation into groups of five animals and subsequently
biweekly for 5 wk. Primary tumors were removed from anesthetized mice
using blunt instrument dissection. All animal experiments were approved
by The Experimental Animal Committee, The Danish Ministry of Justice
and were performed at the animal facility core at University of Southern
Denmark. The mice were housed under specific pathogen-free conditions
with ad libitum food and drinking water. The mice were euthanized if they
showed any adverse signs or symptoms of disease including weight loss,
paralysis, or general discomfort.
Ex vivo pretreatment of cancer cells with anti-human CD73
mAb
Cells were harvested by scraping, then were washed and incubated with
anti-CD73 AD2 mAb (10 mg/ml), anti-CD73 IE9 mAb (10 mg/ml), or
control mAb (10 mg/ml) at 37˚C for 2 h. For flow cytometry analysis of
CD73 expression, the cells were washed three times in ice-cold PBS and
subsequently stained with Alexa Flour 647 goat anti-mouse Ab at 4˚C or
incubated with a second round of primary Ab at 4˚C for 30 min before
staining with Alexa Flour 647 goat anti-mouse Ab. Analysis of the re-
expression of CD73 was performed by AD2 incubation at 37˚C followed
by washing three times and subsequent 3-h incubation in complete me-
dium without AD2 at 37˚C. Thereafter, the cells were washed three times
and then incubated with a second round of AD2 Ab at 4˚C for 30 min before
Alexa Flour 647 goat anti-mouse Ab staining.
Data acquisition and analysis was performed as described in the Flow
Cytometry section.
Before tail vein injections, the cells were resuspended in PBS at a con-
centration of 5 3 106/ml and 0.2 ml was injected into the tail vein of 6- to
8-wk-old female CB-17 SCID mice.
In vivo imaging
Relative quantification of tumor burden and metastasis development was
performed weekly using whole-body bioluminescent imaging (IVIS
Spectrum; Caliper Life Science). Mice were injected with D-luciferin
(150 mg/kg body weight) and then anesthetized with isoflurane gas. Images
were acquired starting 10 min after luciferin injection. Regions of interest
(ROI) were drawn around the mammary fat pad tumor. Further, ROIs were
drawn encircling each of the two lungs to quantify metastases. The photon
emission transmitted from the ROIs was quantified in photons/s/cm2/sr
using Caliper Life Science Living image (version 4.0). The animals were
euthanized 10 min after luciferin injection to image excised organs, and organs
were imaged 2 min later.
Flow cytometry
Subconfluent cells in culture were washed in PBS, harvested by scraping,
and washed (3003 g, 5 min, 4˚C) in DMEM supplemented with Complete
Mini Protease Inhibitor mixture (complete DMEM; Roche Diagnostics).
PBMCs were isolated using standard Ficoll-Paque according to manu-
facturer’s protocol (GE Healthcare). Cells (1 3 105) were incubated with
10 mg/ml anti-CD73 AD2 mAb, anti-CD73 IE9 mAb, or control mAb for
30 min at 4˚C, washed twice in complete DMEM, and incubated with an
Alexa Flour 647 goat anti-mouse Ab (Invitrogen) for 60 min at 4˚C. The
cells were then washed, resuspended in PBS, and analyzed on a FACS-
Calibur (Becton Dickinson). The collected data were analyzed using FlowJo
software (Tree Star).
Inhibition of catalytic activity
Cells (5 3 104) were resuspended in 100 ml glycine buffer (75 mM gly-
cine, 5 mM MgSO4, pH 7.4) containing various concentrations of anti-
CD73 AD2 mAb, anti-CD73 IE9 mAb, control mAb, or 0.1 mM APCP
(Sigma Aldrich). Cells treated with Ab or APCP were analyzed with and
without 0.2 mM AMP and incubated for 3 h at 37˚C. When analyzing the
catalytic activity of cancer cells in the setup resembling the tail vein in-
jection experiments, cancer cells were incubated with anti-CD73 AD2
mAb, anti-CD73 IE9 mAb, or control mAb for 2 h, washed three times in
TBS, resuspended in glycine buffer with and without 0.2 mM AMP, and
incubated for 1 h at 37˚C. After incubation with AMP, 50 ml of 0.5 M
H2SO4 was added to each well, followed by 50 ml phosphate reaction solu-
tion (0.4% NH4-molybdate, 10% ascorbic acid), and incubated for 30 min
at room temperature while shaking to measure the generated inorganic
phosphate, that is, the conversion of AMP to adenosine. The color-reaction
product (molybdenum blue) was colorimetrically measured at 560 nm using
a Victor3 Multilabel Plate Reader (PerkinElmer Life Sciences). The catalytic
activity was determined by subtracting the values in the absence versus the
presence of AMP.
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Soft agar assay was performed as previously described by Ke et al. (13) with
minor modifications. In brief, a prelayer of 25 ml prewarmed 23 IMDM
(Invitrogen) and 25 ml 1.2% agar (Sigma) was plated into 96-well micro-
plates. MDA-MB-231 cells (5 3 103) were seeded on top of the prelayer in
20 ml 23 IMDM and 30 ml 0.8% agar containing anti-CD73 AD2 mAb or
10 mg/ml control mAb. Finally, a semisolid feeder top layer of 25 ml 23
IMDM and 25 ml 0.2% agar were seeded on top of the cell-containing layer.
The cells were incubated in a humidified atmosphere of 5% CO2 and 37˚C
for 12 d. Anchored independent growth was quantified by bioluminescence
using a Victor 3 Multilabel Plate Reader.
Cell migration assay
Migration assays were performed as previously described with minor
modifications (14). After MDA-MB-231 cells (5 3 105cells) were seeded
in six-well plates, a scratch was performed using a pipette tip. After washing
for four times in PBS, 3 ml serum-free DMEM containing 10 mg/ml anti-
CD73 AD2 mAb or control mAb was added. Snapshots of migrating cells
were taken after 3 and 48 h using a Nikon Coolpix P5100 camera mounted
on a Leica DMIL microscope and converted into segmented dark-field
images in Photoshop. The comparison of migration after Ab treatment was
performed by quantifying the segmented dark-field images using ImageJ.
Each scratch was normalized to the quantification of the starting point 3 h
postscraping.
Immunofluorescence microscopy
Cells (1 3 105) were seeded in 12-well plates on coverslips and, 24 h
postseeding, incubated with anti-CD73 AD2 mAb (IgG or Fab9, 10 mg/ml)
or anti-CD73 IE9 mAb (10 mg/ml) for 2 h at 37˚C. After incubation, the
cells were counterstained for 10 min with 5 mg/ml Alexa 633–conjugated
wheat germ agglutinin (Invitrogen), washed in PBS, and fixed for 15 min
with 4% formaldehyde. After permeabilization using 0.05% Triton-X 100
(Bio-Rad Laboratories), the cells were blocked with 1% BSA (Sigma-Aldrich)
before staining with Alexa Fluor 488–conjugated anti-mouse Ab (Invitrogen)
for 30 min at 4˚C. The coverslips were mounted on glass slides in antifade
mounting medium (Invitrogen). Imaging was performed with an Olympus
FV1000 confocal laser-scanning microscope using laser lines 405, 488, and
635 for excitation, appropriate emission filters, and 203 NA:0.95 water
immersion objective.
Live cell fluorescence microscopy
Cells (13 105) were seeded in 12-well plates on coverslips. After 24 h, the
cells were washed, incubated with Alexa Fluor 555–conjugated anti-CD73
AD2 mAb (10 mg/ml) for 10 min and washed again before monitoring with
spinning disc microscopy performed with a Nikon Eclipse Ti (Nikon In-
dustries) microscope equipped with a Yokogawa CSU-X1 spinning disc unit
(Yokogawa Electric Corporation), Andor Laser launcher, and an Andor
EMCCD (Andor Technology) for detection. Imaging was performed using
the 561 laser line for excitation and a 593/40 emission filter. The inte-
gration time was 40 ms, and a 603 oil objective was used.
Immunohistochemistry
Generation of tissue arrays of cell line–derived tumors and staining pro-
cedures were performed as previously described (2, 15).
Proliferation assay
Cells were incubated with anti-CD73 AD2 mAb (0.01–10 mg/ml) or control
mAb (0.01–10 mg/ml) at 37˚C for 2 h. Cells (53 103) were seeded in 96-well
plates in quintuplicate. After 96 h, proliferation was measured in an MTT
proliferation assay (Invitrogen) according to the manufacturer’s guidelines.
Statistics
The statistical significance of bioluminescence measurements of tumor
growth or metastasis in different groups was calculated using Student t test
or random-effect models when appropriate. The p values .0.05 were con-
sidered nonsignificant.
Results
Anti-human CD73 mAb binds human, but not mouse, CD73
and detects human xenograft tumors in mice
Flow cytometry analysis showed that anti-CD73 AD2 mAb (AD2
mAb) and anti-CD73 IE9 mAb (IE9 mAb) both recognized CD73
on the human breast cancer cell lines LM3 and MDA-MB-231, but
failed to detect the murine CD73 variant expressed on isolated
mouse mononuclear hematopoietic cells (Fig. 1A). Furthermore,
when cells were costained with AD2 and IE9 mAbs, the saturation
signals increased compared with staining with each Ab alone,
indicating that AD2 and IE9 recognize different epitopes on CD73
(Supplemental Fig. 1A). The expression of CD73 in LM3 is ∼20%
of that in MDA-MB-231 cells.
The specificity of AD2 mAb toward human CD73 was further
tested by injecting Alexa Fluor 647–labeled AD2 mAb or control
mAb into mice with xenograft tumors established from LM3 breast
cancer cells. In vivo fluorescence bioimaging showed that only
AD2 mAb detected the primary tumor, and that the AD2 mAb
remained visible above background after 72 h (Fig. 1B). No ac-
cumulation of AD2 mAb was observed in any mouse organs, dem-
onstrating that the AD2 mAb only recognizes human CD73, and
not murine host CD73.
Anti-human CD73 mAb inhibits establishment of spontaneous
metastasis, but not primary tumor growth
Next, we examined the ability of AD2 mAb to inhibit primary
tumor growth in vivo. LM3 breast cancer cells were inoculated into
the mammary fat pad of immunodeficient mice. Starting from day 4
after cancer cell implantation, mice received AD2 mAb (n = 5,
5 mg/kg) or control mAb (n = 5, 5 mg/kg) i.p. twice a week for 5 wk,
whereas the primary tumor growth was simultaneously quantified
using bioluminescence imaging. No difference in growth rate of
FIGURE 1. The anti-human CD73 mAb binds human, but not murine,
CD73 and persists within tumors for at least 72 h after treatment. (A) Flow
cytometry analysis showing binding of the anti-CD73 AD2 mAb and anti-
CD73 IE9 mAb to human MDA-MB-231 and LM3 cells, but not to murine
mononuclear cells (black solid line). No binding of control mAb (gray
dashed line) was observed for MDA-MB-231, LM3, or murine PBMCs.
(B) Alexa Fluor 647–labeled anti-human CD73 mAb or control mAb were
injected i.p. in LM3 tumor-bearing mice. Fluorescence corresponding to
the level of mAb binding to the primary tumor was measured after 24, 48,
and 72 h using an IVIS Spectrum instrument.
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the tumors was observed between the two groups when the rela-
tive light emission was compared, indicating that AD2 mAb does
not inhibit primary tumor growth (Supplemental Fig. 1B, 1C).
Furthermore, MTT proliferation assays showed that AD2 mAb
had no effect on the proliferation of cancer cells in vitro (Sup-
plemental Fig. 1D, 1E), demonstrating that the AD2 mAb is neither
cytostatic nor cytotoxic, supporting the in vivo observations.
We next examined whether AD2mAb had an effect on the ability
of cancer cells to establish spontaneous metastasis in the lungs. The
primary tumors were surgically removed 5 wk after LM3 cancer
cell inoculation when they reached a size of 1.2 cm in diameter,
and the metastatic burden in the lungs was quantified weekly for
5 wk using bioluminescence (Fig. 2A). At end point, 10 wk after
LM3 cancer cell inoculation, the overall metastatic burden was 20
times lower in the mice treated with AD2 mAb (n = 5) than those
treated with control mAb (n = 5; p , 0.05; Fig. 2B), demonstrating
that the AD2 mAb inhibits spontaneous metastasis formation. Be-
cause the complement system is still active in CB-17 SCID mice
and may be involved in the elimination of cancer cells, we exam-
ined the complement activation factor C3d deposits in the primary
tumors from mice treated with AD2 mAb and control mAb by
immunohistochemistry and found no indication of complement
activation by the AD2 mAb or control mAb (Supplemental Fig.
1F, 1G).
Because migration of cancer cells is central in the metastatic
process, we investigated whether AD2mAb inhibited the migratory
potential of cancer cells in vitro. However, comparing the migration
of cancer cells in a wound-healing scratch assay showed no dif-
ference between cancer cells treated with AD2mAb compared with
those treated with control mAb (Supplemental Fig. 2A).
Ex vivo preincubation of LM3 cells with anti-CD73 AD2 mAb
inhibits colonization, extravasation, or both
To further study how the anti-human CD73mAbs inhibit metastasis
development, we pretreated LM3 (106) cells with 10 mg/ml AD2
mAb or control mAb ex vivo and injected the cells into the tail
vein of immunodeficient mice (n = 6 in each group) to study the
process of extravasation, colonization, or both. Ex vivo incubation
of LM3 cells with AD2 mAb significantly inhibited metastasis
formation when compared with LM3 cells incubated with control
mAb (p , 0.05; Fig. 3A). Furthermore, no visible metastasis was
detected (0/6) in lungs from mice injected with AD2 mAb-treated
LM3 cells examined ex vivo by bioluminescence, whereas metas-
tases were present in five of six mice injected with control mAb-
treated LM3 cells. Furthermore, ex vivo examination of excised rib
cages from mice injected with LM3 cancer cells revealed that
bone metastases were present in 100% (3/3) of mice treated with
control mAb, but in none of those treated with AD2 mAb. This
demonstrates that AD2 mAb inhibits bone and lung metastasis. It
should be noted that bone metastases were present in animals with
no detectable lung metastases, suggesting that the bone metastases
were not secondary to lung metastases (Fig. 3B).
Ex vivo preincubation of MDA-MB-231 with anti-CD73 AD2
mAb, but not anti-CD73 IE9 mAb, inhibits metastasis
formation in mice
To further study the anti-human CD73 mAb effect on metastasis
development, we pretreated another human metastatic breast cancer
cell line, MDA-MB-231 (106) cells with 10 mg/ml AD2 mAb, IE9
mAb, or IgG control mAb ex vivo and injected the cells into the tail
vein of immunodeficient mice (n = 6 in each group). AD2 mAb
FIGURE 2. Anti-CD73 AD2 mAb inhibits metastasis in a spontaneous
metastasis model. LM3 cells (106) were transplanted into the mammary
fat pad of SCID mice, and anti-CD73 AD2 mAb (5 mg/kg) or control mAb
(5 mg/kg) were administered at day 4 and subsequently twice a week for
5 wk. (A) After surgical removal of the primary tumors, the animals were
imaged weekly for potential lung metastasis by measuring luciferase activity
in the lungs using an IVIS Spectrum instrument. (B) Nonspecific reflec-
tion of light on paws was graphically removed. End-point measurements
(5 wk after primary tumor removal) of photon radiance per area were
compared between the two groups of five animals each using the Student
t test (*p , 0.05).
FIGURE 3. Ex vivo incubation of LM3 cells with anti-CD73 AD2 mAb
inhibits metastasis formation after i.v. injection. LM3 cells (1 3 106) were
incubated ex vivo with anti-CD73 AD2 mAb or control mAb for 2 h and
subsequently injected into the tail vein of female CB-17 SCID mice. (A)
Lung metastasis development in mice, injected with LM3 cells incubated
ex vivo with either anti-CD73 AD2 mAb or control mAb (n = 6 per group),
was monitored by bioluminescence imaging (photon radiance per area
from the lung region), and the results at week 16 were compared using
Student t test (*p , 0.05). (B) Metastasis development in four represen-
tative excised lungs and rib cages (week 16) from mice injected with LM3
cells incubated ex vivo with either anti-CD73 AD2 mAb or control mAb, as
determined by bioluminescence imaging (excised lungs and corresponding
rib cages from the same animal are depicted in the same row).
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preincubation significantly reduced MDA-MB-231–derived lung
metastasis formation compared with those preincubated with con-
trol mAb (p , 0.05; Fig. 4A, 4B). In contrast, IE9 mAb did not
inhibit metastasis formation of MDA-MB-231 compared with con-
trol mAb-treated cells (Fig. 4D, 4E).
Immunohistochemical staining with an anti–pan-cytokeratin Ab
of lungs from mice injected with MDA-MB-231 cells treated with
either AD2 mAb or control mAb demonstrated a significantly
lower number of metastatic foci in the lungs of mice injected with
MDA-MB-231 cells treated with AD2 mAb compared with those
injected with MDA-MB-231 cells treated with control mAb (Fig.
4C; p , 0.001). Furthermore, the size of the metastases was gen-
erally smaller in the AD2 mAb-treated versus control mAb-treated
group, in agreement with the bioimaging results. The metastasis
was located in the alveolar parenchyma, both in the alveolar wall
and in the alveolar lumen, and did not differ between the two treated
groups. No stromal reaction was observed, and the overall structure
of the lung was normal.
Next, we reduced the MDA-MB-231 cell surface expression of
CD73 by CD73 siRNA transfection and observed only 20–30%
expression of normal levels (Supplemental Fig. 2B). Incubation
of these cells with AD2 mAb followed by tail vein injection into
immunodeficient mice (n = 6 in each group) continued to inhibit
metastasis formation in the lungs compared with controls, indi-
cating that AD2 mAb treatment inhibits metastasis formation even
for cancer cells with significantly reduced CD73 expression levels
(Fig. 4F, 4G).
The growth rate of metastases already established in the lungs
was equal in the two treated groups (AD2 mAb versus control mAb)
in both the spontaneous and tail vein metastasis models, indicating
that the Ab affected the establishment of the cancer cell’s ability to
extravasate and/or colonize the lungs, but not the proliferation rate
FIGURE 4. Ex vivo incubation of MDA-MB-231 cells with anti-CD73 AD2 mAb, but not anti-CD73 IE9 mAb, inhibits metastasis formation after i.v.
injection. MDA-MB-231 cells (1 3 106) were incubated ex vivo with anti-CD73 AD2 mAb, anti-CD73 IE9 mAb, or control mAb for 2 h and subsequently
injected into the tail vein of female CB-17 SCID mice. (A) Lung metastasis development in mice, injected with MDA-MB-231 cells incubated ex vivo with
either anti-CD73 AD2 mAb or control mAb, was monitored by weekly bioluminescence imaging (each row depicts the 2 3 6 animals at a given week,
1–5 wk). (B) The relative photon radiance per area from the pulmonary region in live animals (n = 6 per group) at week 6 was compared using a Student
t test (*p, 0.05). (C) Furthermore, the metastasis development was evaluated by comparing the number of metastatic foci by immunohistochemistry (n = 6
per group) at week 6 using the Student t test (*p , 0.001). (D) In a second experiment, metastasis development in mice injected with MDA-MB-231 cells
incubated ex vivo with either anti-CD73 AD2 mAb, anti-CD73 IE9 mAb, or control mAb was monitored by bioluminescence imaging. (E) The relative
photon radiance per area from the pulmonary region of live animals (n = 5 per group) at week 6 was compared using Student t test (anti-CD73 AD2 mAb versus
control mAb: *p, 0.05, anti-CD73 IE9 mAb versus control mAb: *p. 0.05). (F) The effect of AD2 mAb on metastasis development in animals injected with
MDA-MB-231 cells that reduced CD73 levels (transfected with CD73 siRNA) incubated ex vivo was evaluated using bioluminescence. (G) The relative photon
radiance per area from the pulmonary region of live animals (n = 10 per group) at week 7 was compared using the Student t test (*p , 0.05).
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(p. 0.05, random-effects model statistics). A critical step in cancer
cell survival and metastasis after entry into the circulation is their
ability to establish anchor-independent growth. However, cancer
cells treated with AD2 mAb showed no impaired ability of anchor-
independent growth compared with cancer cells treated with control
mAb, as determined by a soft-agar anchor-independent growth as-
say (Supplemental Fig. 2C).
Anti-CD73 AD2 mAb has negligible influence on the catalytic
activity of CD73
Treatment of MDA-MB-231 and LM3 cells with AD2 mAb (up to
70 mg/ml) reduced the catalytic activity of CD73 in vitro by only
18 6 4.35 (SD) and 49 6 1.81%, respectively, compared with
control mAb-treated cells (Fig. 5A, 5B). In contrast, the selective
CD73 inhibitor APCP promoted a 93 6 1.5 and 96 6 3.14% in-
hibition of the catalytic activity of CD73 in MDA-MB-231 and LM3
cells, respectively (Fig. 5A, 5B).
To reiterate the setup of the tail vein injection experiments, we
measured the catalytic activity of CD73 inMDA-MB-231 and LM3
cells when excess Ab was removed after preincubation of the
cancer cells with AD2 mAb and IE9 mAb in vitro for 2 h at 37˚C.
The catalytic activity after AD2 mAb and IE9 mAb treatment
decreased 11 6 6.64 and 40 6 18.9%, respectively, in MDA-MB-
231 (Fig. 5C). Preincubation of LM3 cells with AD2 mAb dem-
onstrated a 52 6 3.0% inhibition of CD73 catalytic activity,
whereas preincubation of LM3 cells with IE9 mAb resulted in a
remarkable 91 6 4.85% inhibition of CD73 catalytic activity (Fig.
5D). Interestingly, CD73 activity in LM3 cells after AD2 mAb
treatment increased ∼20% only 3 h after removal of excessive Ab,
demonstrating a short-lived effect of anti-CD73 mAbs, indicating
the effect on the catalytic activity is functionally unimportant in an
in vivo setting where a longer lasting effect is preferred (Fig. 5D).
It should be noted that the effect of APCP was lost after washing
the cells (Fig. 5C, 5D). Interestingly, upon knockdown of CD73 to
∼50% in the highly expressing MDA-MB-231 cell line, no reduc-
tion in catalytic activity was observed compared with untransfected
cells (Fig. 5E).
Anti-CD73 AD2 mAb and Fab9 fragments of AD2 mAb, but not
anti-CD73 IE9 mAb, induce alterations of CD73 distribution in
the plasma membrane
The distribution of CD73 in the plasma membrane upon AD2 mAb
incubation was investigated using live cell confocal immunoflu-
orescence microscopy. AD2 mAb incubation of MDA-MB-231
cells at 37˚C induced clustering of CD73 in the membrane and
subsequent internalization of CD73 commencing ∼10 min after
incubation began (Fig. 6A, Supplemental Video 1). In contrast, the
IE9 mAb induced minimal, if any, clustering and internalization of
CD73 in MDA-MB-231 cells, indicating that the clustering and
internalization of CD73 is epitope dependent (Fig. 6B). Interest-
ingly, Fab9 fragments of the AD2 mAb also induced clustering and
internalization of CD73 upon incubation of MDA-MB-231 cells,
indicating that the clustering and internalization of CD73 is not
dependent on cross-linking of CD73 (Fig. 6B).
Internalization of anti-CD73 mAbs was further investigated
using flow cytometry of live cancer cells. Analysis of CD73 ex-
pression after AD2 mAb incubation at 37˚C and a subsequent round
of AD2 incubation at 4˚C showed that the mean fluorescence in-
tensity (MFI) of CD73 staining decreased in MDA-MB-231 and
LM3 cells compared with cells incubated at 4˚C, whereas no de-
crease in CD73 MFI was observed after IE9 mAb incubation of
MDA-MB-231 cells (Supplemental Fig. 3A). An increased MFI
was observed after incubation of LM3 cells with IE9 mAb at 37˚C
compared with 4˚C, which further supports that IE9 does not induce
internalization of CD73 (Supplemental Fig. 3A). Analysis of CD73
expression in MDA-MB-231 omitting the second round of AD2
mAb incubation at 4˚C showed a slight decrease in MFI com-
pared with those incubated with two rounds of AD2, suggesting a
minor re-expression of CD73 during the incubation period at
37˚C (Supplemental Fig. 3B). This decrease in MFI was not ob-
served in LM3 cells (Supplemental Fig. 3B). Furthermore, analysis
of CD73 expression after AD2 incubation at 37˚C and subsequent
incubation in Ab-free medium showed that only ∼10% of CD73
was re-expressed after 3 h (Supplemental Fig. 3B).
Discussion
CD73 has recently been proposed as a target for anticancer therapy
(8, 9, 11), because treatment of mice with anti-murine CD73 mAb
affects tumor progression by inhibiting the CD73-mediated pro-
FIGURE 5. Anti-human CD73 mAb has a negligible influence on CD73
catalytic activity compared with APCP. The catalytic activity of CD73 in
cancer cells was determined by measuring the generated inorganic phos-
phate from the enzymatic cleavage of AMP. (A) The catalytic activity in
MDA-MB-231 cells treated with anti-CD73 AD2 mAb or APCP for 3 h
relative to untreated control cells. (B) The catalytic activity in LM3 cells
treated with anti-CD73 AD2 mAb or APCP for 3 h relative to untreated
control cells. (C) The catalytic activity in MDA-MB-231 cells after pre-
treatment with anti-CD73 AD2 mAb, anti-CD73 IE9 mAb, or APCP fol-
lowed by washing, thus resembling the in vivo tail vein injection experiments
relative to untreated control cells. (D) The catalytic activity in LM3 cells
after pretreatment with anti-CD73 AD2 mAb, anti-CD73 IE9 mAb, or APCP
followed by washing, thus resembling the in vivo tail vein injection ex-
periments relative to untreated control cells. The anti-CD73 AD2 mAb (long-
term activity) bar describes the relative catalytic activity in LM3 cells
incubated for 2 h, washed, and incubated in full medium for 3 h without
anti-CD73 AD2 mAb as compared with untreated control cells. (E) Catalytic
activity in MDA-MB-231 cells after siRNA knockdown of CD73 and un-
transfected cells. CD73 expression after siRNA knockdown was ∼50%.
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duction of adenosine. In this study, we provide novel insight to the
role of CD73 in metastasis development and a novel mechanism
by which some anti-CD73 Abs can inhibit metastasis formation
independent of the catalytic activity of CD73. Our study indicates
that CD73 redistribution, induced by anti-CD73 AD2 mAb (AD2
mAb), is central in the inhibition of human breast cancer metastasis
in the lungs. Our data support the growing evidence suggesting
CD73 as an attractive candidate for targeted treatment in breast
cancer, and we suggest using the dual role of CD73 in metastasis
development to increase the efficacy of anti-human CD73 mAb
treatment by targeting the different functions of CD73.
The functions of CD73 can be divided into those relating to its
catalytic activity, converting AMP into adenosine, and those inde-
pendent of such activity, for example, cell adhesion and signal
transduction (10). Most studies on CD73, including those in cancer,
have focused on the functions related to the catalytic activity show-
ing that adenosine has a broad range of effects on tumor progression,
including promoting angiogenesis, immunosuppression, and metas-
tasis development (7–9, 11, 16). It was recently shown that CD73
on cancer cells promotes spontaneous metastasis by enhancing
cancer-cell migration in an adenosinergic manner through the
adenosine A2B receptor and downstream promigratory mecha-
nisms (8). Our in vivo data confirmed a role for CD73 in spon-
taneous metastasis of tumors established from the human breast
cancer line LM3, and although the AD2 mAb exhibited a moder-
ate effect on adenosine production in the LM3 breast cancer cells,
this was shown to be short-lived and, therefore, functionally neg-
ligible. Furthermore, we show that AD2 mAb treatment inhibits
metastasis after tail vein injection of MDA-MB-231 cells, but has
only a slight effect on the catalytic activity in vitro. Moreover, when
80% of adenosine generating CD73 was removed by siRNA
knockdown in MDA-MB-231 cells, AD2 mAb continued to signif-
icantly inhibit metastasis, further suggesting that the antimetastatic
effect of AD2 mAb is independent of catalytic activity. Taken
together, our data add yet another mechanism of CD73 in me-
tastasis formation in human breast cancer in addition to the cat-
alytic activity. Moreover, the inhibitory effect of AD2 mAb on
metastasis development was significant in the CD73-expressing
LM3 and MDA-MB-231 cells, as well as the CD73 siRNA-treated
MDA-MB-231 cells with reduced level of CD73, suggesting that
the anti-metastatic effect of AD2 mAb is independent of CD73 ex-
pression levels.
Our study showed that AD2 mAb inhibited metastasis formation
whereas having no effect on the growth of established primary
tumors or metastasis. Furthermore, we showed that ex vivo pre-
incubation of human cancer cells with AD2 mAb inhibited me-
tastasis after tail vein injection, which circumvents the early steps
of the metastatic process, suggesting that CD73 promotes an es-
sential function in extravasation, colonization, or both. Together,
this indicates that AD2 mAb inhibits metastasis formation inde-
pendent of an effect on the primary tumor. This suggestion is
supported by our previous study with isogenic cancer cell lines
wherein we identified CD73 as one of the markers overexpressed
in the cancer cell line that was capable of colonization in distant
organs compared with its isogenic partner: a cancer cell line that
could spread from the primary tumor but remained dormant in
the distant organ (17).
Incubation of the breast cancer cells with AD2 mAb and AD2
Fab9 fragments, but not anti-CD73 IE9 mAb (IE9 mAb) in vitro,
caused CD73 to cluster and subsequently internalize, indicating
that the process is epitope specific, but does not depend on cross-
linking of CD73. It is well recognized that although some cell-
surface proteins are internalized only when cross-linked by one or
two layers of Abs (primary and secondary Abs), other receptors are
internalized by binding of Fab9 fragments of an Ab (18–20). IE9
and AD2 mAbs are both generated from mice immunized with full-
length native CD73, however, as we showed IE9 and AD2 mAbs
recognized different epitopes about which little is known other than
the fact that IE9 mAb, in contrast with AD2, recognizes denatured
CD73, suggesting that IE9 recognizes a linear epitope of CD73,
whereas AD2 mAb recognizes a conformational epitope.
Ex vivo preincubation ofMDA-MB-231 tumor cells with IE9 did
not significantly inhibit metastasis development compared with
control mAb-treated tumor cells. Treatment of cancer cells with
FIGURE 6. Anti-human CD73
mAb causes clustering and subsequent
internalization of CD73 at 37˚C. Im-
munofluorescence imaging of the
subcellular localization of CD73 after
anti-CD73 AD2 mAb, anti-CD73 IE9
mAb, or anti-CD73 AD2 Fab9 frag-
ment treatment. (A) Representative
time points from live cell fluores-
cence microscopy imaging of MDA-
MB-231 cells incubated with Alexa
Fluor 555 anti-CD73 AD2 mAb (red)
over 1.5 h at 37˚C. (B) CD73 (green)
distribution after treatment of MDA-
MB-231 cells with anti-CD73 AD2
mAb, anti-CD73 IE9 mAb, or anti-
CD73 AD2 Fab9 fragments for 2 h at
37˚C. Phase-contrast images were
merged with the fluorescence images
to depict cellular location of CD73.
Original magnification 360.
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AD2 mAb, but not IE9, might trigger alterations of CD73 distri-
bution in the plasma membrane and internalization, disrupting
prometastatic functions of CD73. The internalization of CD73
might occur concomitantly as a result of CD73 redistribution, and
the lower CD73 expression resulting from internalization might not
cause inhibition of metastasis development per se. Although the
fluorescent microscopy and the flow cytometry data of AD2 mAb
supported each other, the readouts were not directly proportional,
likely because of technical rather than biological reasons. Re-
expression of CD73 in MDA-MB-231 cells after 3-h incubation
with AD2mAb at 37˚C were shown to be only ∼10%. A recent study
suggested that CD73, upon ligand binding, might interact with other
membrane proteins and cytoskeleton components to promote cell-
stroma adhesion (21). AD2-induced reorganization of CD73 on the
surface of the tumor cells, sustained for a substantial period of time,
might prevent metastasis development through interference with
these proposed intermembrane interactions. Although inducing in-
ternalization of CD73 AD2 had no effect on the enzymatic activity,
knockdown of CD73 to ∼50% in the highly expressing MDA-MB-
231 cell line resulted in no reduction in catalytic activity compared
with untransfected cells. These data indicate that, in cells expressing
high levels of CD73, these levels are not directly proportional to
the enzymatic activity.
Based on data showing CD73 clustering and internalization, we
propose that CD73, independent of its function as an adenosine-
generating enzyme, acts as an adhesion and/or signaling molecule.
This is also supported by the study of Zhi et al. (12) showing that
knockdown of CD73 in human metastatic MDA-MB-231 cells
more efficiently prevented adhesion to the extracellular matrix than
APCP treatment. This study did not demonstrate the impact of
siRNA knockdown of CD73 on metastasis development; however,
because our data indicate the effects of AD2 mAb treatment are
independent of CD73 expression levels, it would be interesting to
investigate the direct correlation between CD73 expression and
metastasis development. Dual roles of other GPI-anchored CD
proteins have previously been demonstrated. CD157, which exhibits
ADP-ribosyl cyclase and cyclic ADP ribose hydrolase activities, has
been shown to be important for neutrophil migration and adhesion
independent of the catalytic activity of CD157 (22).
Recent studies wherein cancer cells were injected into the tail
vein of syngeneic mouse models with various cancer types showed
that treatment with APCP or anti-murine CD73 mAb before cancer
cell injection inhibited lung metastasis independent of T and NK
cells, suggesting that CD73 expressed by other host cells, for ex-
ample, endothelial cells, also plays an important role in the ability of
circulating tumor cells to metastasize (11, 23). Because AD2 mAb
recognizes only human and not murine CD73, we conclude that
the metastasis formation and inhibition thereof observed in our
animal models is dependent solely on the CD73 expressed on the
human cancer cells. It should be noted, however, that in humans,
we cannot exclude a metastasis-promoting function of CD73 of
normal adjacent cells, including endothelial cells, present in the
metastatic niche. These cells should also be blocked by systemic
treatment with anti-human CD73 mAb.
Studies in syngenic breast cancer mouse models have shown that
the tumor-promoting effect of CD73 was mediated through the
enzymatic function of CD73 by inhibiting the T cell–mediated
antitumor response (8, 9, 11). Because our animal studies were
performed in xenograft models using immunocompromised ani-
mals, the effect of CD73 on the immune system could be ruled
nonimportant in our model. However, an Ab designed to inhibit
catalytic activity of CD73 in human breast cancer would probably,
in the presence of a functional immune system, favor an antitumor
immune response leading to inhibition of primary tumor and
metastasis growth.
In this study, we show that an anti-human CD73mAb reduces the
ability of circulating human cancer cells to establish secondary
tumor foci by inducing CD73 clustering and internalization. The
metastatic effect of CD73 seems independent of its catalytic function
of generating adenosine, but is instead attributable to the adhesive
and/or signaling properties of CD73. Our data suggest that a mixture
of anti-human CD73 Abs targeting different functions of CD73,
such as adhesion and catalytic activity, would be therapeutically
beneficial and also reduce the risk for developing resistance toward
the anti-CD73 mAb treatment.
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Supplemental Figure 1. (A) Flow cytometry analysis of anti-CD73 AD2 mAb (black line), anti-CD73 IE9 
mAb (solid gray), combination of anti-CD73 AD2 mAb and anti-CD73 IE9 mAb (tinted black line) and 
control mAb ( gray line) in LM3 cancer cells. (B) LM3-2 cells (106) were transplanted into the mammary fat 
pad of female CB-17 mice and anti-CD73 AD2 mAb (5 mg/kg) or control mAb (5mg/kg) was administered 
at day 4 and subsequently twice a week for 5 weeks. A representative mouse from each group was imaged 
weekly for luciferase activity using the IVIS Spectrum instrument. (C) Comparison of photon radiance per 
area between the two groups of mice at week 5 using a Student’s t-test (p>0.05). (D) MDA-MB-231 and (E)
LM3 cells were grown for 96 h after incubation with anti-CD73 AD2 mAb or control mAb and proliferation 
was subsequently measured using the MTT assay. (F-G) Immunohistochemical analysis of complement 




Supplemental Figure 2. Anti-CD73 AD2 mAb does not inhibit migration or anchor independent growth of 
cancer cells in vitro. (A) Migration of MDA-MB-231 cells treated with either anti-CD73 mAb or control 
mAb in a premade scratch after 48h was evaluated by comparing the quantification of segmented darkfield 
images of migrating cells using Image J. Each scratch was normalized to the quantification of the starting 
point 3h post-scraping. (B) CD73 expression in MDA-MB-231 cells 96h after siRNA transfection with two 
different CD73-specific siRNAs relative to CD73 expression in control scrambled siRNA transfected cells. 
(C) MDA-MB-231 cells were incubated in the mid layer of three semisolified soft agar layers supplemented 
with growth medium and either anti-CD73 AD2 mAb or control mAb for 12 days. Anchored independent 





Supplemental Figure 3. Anti-CD73 AD2 mAb, but not anti-CD73 IE9 mAb, decreases cell surface 
expression of CD73 at 37°C compared to incubation at 4°C. (A) CD73 surface expression in MDA-MB-231 
and LM3 was determined by flow cytometry following incubation of tumor cells with anti-CD73 AD2 mAb, 
anti-CD73 IE9 mAb at 37°C and a second round of primary antibody incubation at 4°C as shown by mean 
fluorescence intensity of CD73 signal relative to incubation at 4°C. The MDA-MB-231 AD2 mAb (long 
term effect) bar describes the relative expression in MDA-MB-231 cells following AD2 incubation at 37°C, 
wash, incubation in full medium for 3 hours without anti-CD73 AD2 mAb at 37°C and a second round of 
AD2 at 4 °C compared to incubation at 4°C. (B) CD73 surface expression in MDA-MB-231 and LM3 was 
determined by flow cytometry following incubation of tumor cells with anti-CD73 AD2 mAb, anti-CD73 
IE9 mAb at 37°C omitting the second round of primary antibody incubation as shown by mean fluorescence 
intensity of CD73 signal relative to incubation at 4°C.
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Video Legend. Anti-human CD73 mAb causes clustering and subsequent internalization of CD73 at 37°C.
Live cell fluorescence microscopy imaging of MDA-MB-231 cells incubated with AlexaFluor555 anti-
human CD73 mAb (red) at 37°C. Clustering and internalization of CD73 in a representative time frame of 15 
min starting 10 min after the antibody was added can be seen.
 
